Press Releases

 
Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
May 22, 2017


Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
May 11, 2017


Adamas Reports Inducement Grant to New Chief Operating Officer
May 5, 2017


Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
May 2, 2017


Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
Apr 27, 2017


Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease
Apr 24, 2017


Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting
Apr 18, 2017


Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
Mar 28, 2017


Adamas to Present at the 16th Annual Needham Healthcare Conference
Mar 28, 2017


Adamas Announces New Employment Inducement Grant
Mar 10, 2017


Page:
1
NextLast